Agilent to Buy Digital Pathology Firm Proscia for $240 Million
Agilent Technologies has agreed to acquire Proscia, a provider of digital pathology software, in an all-cash transaction. The deal is valued at $240 million at closing, with up to $30 million more tied to future performance milestones. Proscia serves clinical and life-sciences customers with enterprise digital pathology tools.
Agilent Technologies, which trades on the NYSE under the ticker A, has agreed to acquire Proscia. The deal is structured as an all-cash transaction. Proscia supplies enterprise digital pathology software to customers in clinical care and life sciences.
The purchase price is $240 million in cash when the deal closes, plus up to $30 million tied to future performance milestones. The announcement carried Santa Clara, California, and Philadelphia datelines.
The acquisition could affect hospitals, pathology labs, clinicians, and life-sciences researchers that rely on digital pathology tools. If Agilent invests in and integrates Proscia’s software, diagnostic workflows may become more connected, potentially improving access to specialist review. Consolidation may also shape vendor choice and pricing, though effects on patients and innovation remain uncertain.